STEAMLINING LTBI REPORTING IN KAISER PERMANENTE – MIDATLANTIC STATES

Mona K Gahunia, DO

Associate Medical Director, Operational Excellence Internal Medicine/Infectious Diseases Mid-Atlantic Permanente Medical Group Yonas S Tamrat, MD, MPH, MMSc MAPMG HOPE (KP HealthConnect Optimization & Physician Efficiency) Internal Medicine Mid-Atlantic Permanente Medical Group

KAISER PERMANENTE

Background: Kaiser Permanente Mid-Atlantic States

FAST FACTS

Founded: **1980**


Headquarters: Rockville, Maryland

Comprised of:

- Kaiser Foundation Health Plan of the Mid-Atlantic States, Inc. (8,500+ Employees)
- Mid-Atlantic Permanente Medical Group, P.C. (1,600+ Physicians, 50+ Specialties)

Medical Offices: 31 (14 Urgent Care locations, 6 open 24/7)

Members Served: 750,000+



PERMANENTE MEDICINE® Mid-Atlantic Permanente Medical Group

Background: LTBI reporting

- A new latent tuberculosis (LTBI) reporting regulation went into effect in Maryland in July 2018.
- ▲ State of Virginia followed shortly after with a similar reporting requirement.
- Our medical group set out to establish a streamlined, standardized process for reporting LBTI cases by leveraging our integrated electronic medical record system.
- In the process, we also aim to improve clinical processes for TB screening, LTBI management and monitoring of compliance reporting.

3 © 2020 Mid-Atlantic Permanente Medical Group

Old Reporting Workflow I



Old Reporting Workflow II

Case reporting to the local health department

Search LTBI reporting form (print version, online)




Complete the form manually



Fax local health department


New Reporting Workflow I



PERMANENTE MEDICINE®

Mid-Atlantic Permanente Medical Group

New Reporting Workflow II




PERMANENTE MEDICINE® Mid-Atlantic Permanente Medical Group

Leveraging EHR tools to capture data

- ▲ MAPMG uses KP HealthConnect (based on Epic electronic medical record system).
- We utilized SmartTools to capture data used in letter generation
 - SmartSet: standardized order and documentation template
 - **SmartPhrase**: documentation tool
 - **SmartList**: list of pre-configured choices in SmartPhrases
 - SmartForm: tool for documenting structured data
 - SmartData Element: stores discrete data from SmartLists and SmartForms
 - SmartLink: tool that pulls stored information from SmartData Elements into letters

SmartSet



▼ Treatment

- Use this section for treatment of latent tuberculosis infection in HIV-uninfected nonpregnant adults.
- Contact infectious disease physician on the care team if patient is HIV-positive.
- Patients must be evaluated for active TB before initiating treatment for latent TB.
- Select treatment option based on patient specific factors including adherence to treatment and risk for drug interaction.
- Rifampin based regimen are preferred due to efficacy, high completion rate and low hepatotoxicity.
- Pyridoxine (Vitamin B6) 25-50 mg/d should be given to prevent neuropathy caused by Isoniazid (INH).

Latent TB Treatment Options

- Rifampin 600 mg daily (duration: 4 months) Disp-60 capsule, R-3, Fill Now
- Isoniazid-Rifampin 300-600 mg daily (duration: 3 months)
- O Isoniazid 300 mg daily (duration: 6 months)
- O Isoniazid 300 mg daily (duration: 9 months)

Monitoring During Treatment

 Baseline and routine laboratory monitoring during treatment of LTBI are indicated only when there is a history of liver disease, HIV infection, pregnancy (or within 3 months post-delivery), or regular alcohol use.

LTBI treatment

· Clinical monitoring should occur on a monthly basis to assess adherence, rationale for treatment, and to identify signs or symptoms of adverse drug reactions.

Lab Orders

Liver Function Test

Monitoring lab tests

Liver Function Test (Standing Order for patients with chronic liver disease) Normal, Routine, Expires; 6 Months, Manual-release, Interval; Every 4 Weeks, Count; 6

▼ Diagnoses

LTBI Diagnoses

SCREENING FOR PULMONARY TB [Z11.1]

- Diagnoses
- Patient Instructions (AVS)
- Latent TB: Patient Instructions

U Tuberculin Skin Test (PPD)

Patient Instructions

© 2020 Mid-Atlantic Permanente Medical Group 9

SmartPhrases & SmartLists

SAMPLE NURSE NOTE

Hope Team, PhD came in for reading of the PPD skin test placed on 1/1/2020							
Results have been entered into KP HealthConnect.							
Lab Results							
Component	Value	Date					
PPDINTERP	12	01/01/2020					
PPDINTERP	Positive	01/01/2020					
PPD test is positive - Yes US born: No - Country of birth: Neverland Month/Year arrived in US: 10/2010							

Reason for TB Screening: school/educational screening

Risk factors: Diabetes, Smoking, Hepatitis, Alcohol

HIV status at diagnosis: Negative

Confirm that TB Screening SmartForm has been completed and that data is current with special emphasis to TB sign and symptoms.

SAMPLE PHYSICIAN NOTE

Permanente Medicine

Mid-Atlantic Permanente Medical Group

CHIEF COMPLAINT

TB Screening/LTBI evaluation

SUBJECTIVE

Hope Team, PhD is a 77 yr old adult presenting for tuberculosis screening/LTBI evaluation.

The following information was collected by nursing staff during a recent TB screening visit. U.S. born: No County of birth: Neverland Month/Year arrived in US: 10/2010 Date of first LTBI evaluation: 1/1/2020 Reason for LTBI test: School/education screening HIV status at diagnosis: Negative Risk factors: Diabetes, Smoking, Hepatitis, Alcohol PPD Date read: 1/1/2020 Interpretation: <u>12 mm</u> IGRA Test date: 12/31/2019 Interpretation: <u>POSITIVE</u> Date of CXR/chest imaging: 1/2/2020

CXR/chest imaging result: Not Consistent with TB

Relevant past medical, family and/or social history were reviewed.

OBJECTIVE

VITALS: There were no vitals taken for this visit. GENERAL: Alert, nontoxic HEENT: Mucus membranes moist, normal conjunctiva NECK: Supple Lymphadenopathy: No CARDIAC: Regular rate and rhythm. No murmurs CHEST: clear to auscultation

ASSESSMENT/PLAN

History and physical exam consistent with Latent TB infection. See diagnosis entry for additional diagnoses addressed in this office visit. Diagnoses, treatment plan, and precautions reviewed with patient.

Treatment offered: Yes

Treatment started: Yes - 6 months Isoniazid

Health Maintenance and Proactive Care gaps reviewed and addressed.

Automated Letter Generation

Maryland Latent Tuberculosis Infection (LTBI) Reporting Form

	•					· ·	-		
rovider name: rovider affiliation: rovider telephone:					For Health Depa Confirmed LTBI case numb	Suspected ``	r B Infe	ection 🗆 No	ot a case
		🗆 In	itial Repor	t 🗆 F	ollow-up Report				
Last name	First name	Ν	Aiddle		Date of birth (MM/DD/YYY	Y)	Sex at birth Male Female	Unknown
Address	Uni	t# Cit	y or Town		State	Zip code	Cour	nty of residence	3
Patient telephone	number	U.S born Yes No	Country of	of birth			Mon	th/Year arrived	in U.S.
Race (select all th American Indian or Native Hawaiian/Ot	Alaskan Native		3lack or Africa Other Race		own	Ethnicity Hispanic or L Unknown	atino	🗆 Not Hispa	nic or Latin
		Report	ing Infor	mation	and Risk fac	tors			
Name of reporting agency:				Date of first L	TBI evaluation				
Reporting agency type select one Employment Long-term care facility Correctional facility Immigrant/refugee clinic			Healt	for LTBI test se hcare worker ol/education scre	П Т		to rule out TB ment/administr		
Military		nedical care pro		B-wa				screen (non B	

	🗆 Military	Federally qualified health center		B-waiver	Refugee screen (non B-waiver)
	Local health dept.			Contact investigation. Contact	t 🗆 Other:
	School/daycare	Other:		number, if known:	
	HIV status at diagnos		Risk factors ch	eck all that apply	
		15	Diabetes	End-stage renal disease	Congregate living situation
Negative Positive			Smoking	Homeless within past year	Immune modulating drugs
			Hepatitis	Injection drug use	Pregnancy
Unknown			Alcohol	Non-injection drug use	Other:

Testing a	and Eval	luation
-----------	----------	---------

TST	IGRA	Smear Collection Date:		
Agency:	Test date:	Result: Positive Negative		
Date read:	Test type: QFT T-SPOT Other	Unknown Not done		
	rest type. □ QF1 □ 1-SF01 □ Other	Culture Collection Date:		
Interpretation:	Interpretation: Positive Negative	Result Date:		
Positive Unknown	Unknown Borderline/Indeterminate	Result: Positive Negative		
Negative Not done	□ Not done □ Failed/Invalid	Unknown Not done		
Date of chest radiography or	Chest radiography or Consistent	with TB Not consistent with TB		
other chest imaging:	chest imaging result: Unknown	Not done		
Final evaluation outcome:				

Treatment

Treatment							
Was the patient offered LTBI	treatment? 🗆 Yes	🗆 No	Did the patient start I	.TBI treatment?	🗆 Yes	🗆 No	
Reason patient did not start L	TBI treatment:		LTBI treatment regin	nen prescribed:			
Refused	Referred for treat	ment	9 months Isoniazid				
Provider decision	Referral:		4 months Rifampin				
Previous LTBI treatment			12 weeks Isoniazid/	Rifapentine			
Previous TB treatment		Other:	-				
Lost to follow-up							
LTBI treatment start date: Reason LTBI treatment stopped:							
		Treatr	ment completed	Pregnancy			
Active		e TB developed	Provider decis	sion			
LTBI treatment end date:	BI treatment end date:		o care	Patient moved	1		
		□ Adver	rse event	Died			
		Other:					
Serious adverse event/reaction to LTBI treatment: Hospitalization Death Other:						None	

Maryland Latent Tuberculosis Infection (LTBI) Reporting Form

Provider Name: YONAS S TAMRAT	For Health Department use only: LTBI case status
	□ Confirmed □ Suspected TB Infection □ Not a case
	LTBI case number (if known):
Provider telephone: 703-359-7878	

Initial Report Follow-up Report Last Name First Name Middle Date of birth (MM/DD/YYYY) Sex at birth 3/10/1942 Team Hope female Address County of residence 2101 E Jefferson St Rockville MD 20852 US County of birth Month/Year arrived in US Patient telephone number U.S. born 240-000-0001 No Neverland 10/2010

Race Black/African American

Reporting Information and Risk factors

Ethnicity

Name of reporting agency: Kais Mid-Atlantic States (KPMAS)	ser Permanente		Date of	first LTBI evaluation: 1/1/2020
Reporting agency type Private medical care provider			for LTB education	I test a screening
HIV status at diagnosis: Negative	Risk factors: Diabetes, Smoking, Hepatitis, Alcohol		phol	
	Testing a	nd Evalua	tion	
TST Agency: KPMAS Date read: 1/1/2020 Interpretation: 12 mm	IGRA Test date: 12/31/2019 Test type: QFT Interpretation: F	POSITIVE		Smear Collection Date: Result: Culture:
Date of chest radiography or other chest imaging: 1/2/2020	Chest radiogra	phy or ch	est imag	ing result: Not consistent with TB
Final evaluation outcome: Later	nt TB infection/no	TB		
	Tre	atment		
Was the patient offered LTBI t	reatment? Yes	Did the	patient s	start LTBI treatment? Yes
Reason patient did not start LT	BI treatment:	LTBI ta Isoniazi		regimen prescribed: 6 month

Reason patient did not start Er Br treatm		Isoniazid			
LTBI treatment start date: 1/2/2020	Reason	LTBI treatment stopped:			
LTBI treatment end date:					
Serious adverse event/reaction to LTBI treatment:					

Sending fax from the EHR

LTBI Reporting	- 🗆	x
Fax Numbers Communications		
E LTBI Reporting Fax Numbers	C	^
Click on New Communication button below, then choose LTBI Maryland or LTBI Virginia . The letter should be auto-populated if documentation is performed per recommended workflow. Click Free Text then enter Name and Fax Number from below. Click Send No t button to the fax the form.	w	
Maryland - Center for TB Control and Prevention Fax: 410-767-5972		
<u>Virginia - TB Control</u> Fax: 804-371-0248		
	t t	
Search all contacts 🕂 Add 1 PCP 2 Referring 3 Patient 4 Print For Patient 5 Care Team 6 OB Providers 7 Previous 8 Last 9 Free Text		
> To: No recipient selected		
LTBI Maryland LTBI Virginia Consult Initial Consult Follow Up Copy Letter Other		
🚰 Letter: LTBI Maryland 🗙 From: TAMRAT, YONAS S 🔎 Reason:		
🏠 Times New Roman 🔽 11 🔽 B I U 🛆 ▾ 🌤 🗈 🛅 🗮 🚍 📲 📲 💷 📼 🖘 🅸 🗩 🦥 5 🖓 💭 🛔 hisert SmartText 着 😓 🔿		1
I, C		
Maryland Latent Tuberculosis Infection (LTBI) Reporting Form		
Provider Name: YONAS S TAMRAT For Health Department use only: LTBI case status		
MD Confirmed Suspected TB Infection Not a case		
Provider affiliation: Kaiser Permanente Provider telephone: 703-359-7878		
Initial Report □ Follow-up Report		
Last Name First Name Middle Date of birth (MM/DD/YYYY) Sex at birth		~

Aiming for process improvement that is a Win-Win for All

- ▲ Alignment of all relevant specialties and urgent care
- Physician and staff education on new tools and workflows
- ▲ Implementation of new LTBI screening and reporting process
- Evaluation of effectiveness of new process

Expansion to other reportable diseases

Thank You!

Questions?